According to Mark Cuban on X, GLP-1 drugs bought via LillyDirect are under $500 and falling because no pharmacy benefit manager is involved, while big PBMs charge about $1,300 during the deductible phase and block direct purchases (source: Mark Cuban, Nov 26, 2025). According to Eli Lilly and Company, LillyDirect is an official manufacturer program that offers direct access to select GLP-1 therapies, creating a non-PBM distribution channel relevant to patient out-of-pocket pricing and volume (source: Eli Lilly and Company, 2024 LillyDirect program materials). According to the US Federal Trade Commission, its 2024 interim staff report criticized PBM rebate and steering practices as potentially raising costs, providing regulatory context for employer and payer decisions described by Cuban (source: US Federal Trade Commission, 2024 interim report on PBMs). According to company investor materials, CVS operates CVS Caremark, Cigna operates Express Scripts, and UnitedHealth operates OptumRx, making tickers LLY, CVS, CI, and UNH central for PBM and GLP-1 exposure in trading screens (source: CVS Health, Cigna Group, and UnitedHealth Group investor disclosures). According to the source, no direct impact on BTC or ETH is cited in the post, so crypto market implications are not mentioned by the author (source: Mark Cuban on X, Nov 26, 2025).